NFA
SBBP

Nationwide Fund Advisors’s Strongbridge Biopharma plc. SBBP Stock Holding History

Nationwide Fund Advisors’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,049
Closed -$83K – 2542
2017
Q3 		$83K Hold
12,049
– – ﹤0.01% 2965
2017
Q2 		$86K Buy
+12,049
New +$55.7K ﹤0.01% 2960

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TAF
Tredje AP-fonden Se-111 91 Stockholm, Sweden $22.1B AUM 41.68% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Nationwide Fund Advisors's SBBP Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2017, closing a stake of 12,049 shares — an estimated $83K sold.

Nationwide Fund Advisors first reported a position in SBBP in Q2 2017 and held it in 2 quarters. The position peaked at $86K in Q2 2017. 54 funds tracked by Wall St. Rank hold SBBP as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Strongbridge Biopharma plc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 12,049 Strongbridge Biopharma plc. shares in Q4 2017, an estimated $83K.
  • Nationwide Fund Advisors first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 2 quarters.
  • Nationwide Fund Advisors's Strongbridge Biopharma plc. position peaked at $86K in Q2 2017.
  • 54 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.